CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,859 | 88,567 | ||
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Sale | −4,797 | $16.58 | $80K | 83,770 |
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Sale | −98 | $17.37 | $2K | 83,672 |
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 0 | ||
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,000 | 2,000 | ||
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,750 | 18,750 | ||
| 2026-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,859 | 25,725 | ||
| 2026-01-20 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +3,760 | $1.86 | $7K | 54,657 |
| 2026-01-20 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −3,760 | $18.42 | $69K | 50,897 |
| 2026-01-20 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −3,760 | 8,643 | ||
| 2025-12-18 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +3,760 | $1.86 | $7K | 54,657 |
| 2025-12-18 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −3,560 | $17.87 | $64K | 51,097 |
| 2025-12-18 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −200 | $18.56 | $4K | 50,897 |
| 2025-12-18 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −3,760 | 12,403 | ||
| 2025-11-24 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +37,600 | $1.86 | $70K | 88,497 |
| 2025-11-24 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −37,600 | $17.07 | $642K | 50,897 |
| 2025-11-24 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −37,600 | 16,163 | ||
| 2025-11-06 | DANSEY ROGER D Director | Grant or award · Director Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-11-03 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −6,284 | $12.56 | $79K | 37,592 |
| 2025-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 38,398 |
Page 9 of 20 · 381 trades